Compare SABS & EVTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABS | EVTL |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United Kingdom |
| Employees | 86 | 454 |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.8M | 338.7M |
| IPO Year | N/A | N/A |
| Metric | SABS | EVTL |
|---|---|---|
| Price | $3.37 | $2.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $10.75 | ★ $12.70 |
| AVG Volume (30 Days) | 401.9K | ★ 2.8M |
| Earning Date | 05-12-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.65 | $1.90 |
| 52 Week High | $6.60 | $7.60 |
| Indicator | SABS | EVTL |
|---|---|---|
| Relative Strength Index (RSI) | 41.94 | 38.43 |
| Support Level | $2.84 | $1.90 |
| Resistance Level | $4.09 | $2.89 |
| Average True Range (ATR) | 0.17 | 0.18 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 12.50 | 16.69 |
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero-emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.